Articles tagged with Cancer Cell Lines
A new study found that cancer cells selectively chip away gene-rich sections of the Y chromosome, triggering ripples that regulate tumor growth. The Y chromosome erosion was found to be acquired over time, rather than inherited, and was linked to increased mortality from certain cancers.
A Cornell University-led research group has devised a strategy for capturing cancer-specific protein-to-protein interactions using a photochemically driven labeling technique. They identified SLK as a driver of cancer in certain contexts, which can be co-opted by cancerous cells to drive growth.
Researchers at UT MD Anderson Cancer Center have achieved high response rates in patients with hard-to-treat acute myeloid leukemia (AML) using an all-oral combination therapy. The study also provides insights into the origins of cancer, revealing that tumors evolve rapidly through bursts of genetic changes.
Researchers developed a new approach using the microbial protein Archaerhodopsin-3 to induce apoptosis in cancer cells, leading to significant tumor shrinkage when exposed to green light. The findings, published by Okayama University, show great potential for this light-activated molecule as a novel cancer therapy.
AcCELLerate has partnered with ATCC to provide customized Master, Working, and assay-ready instaCELL banks for research clients. Researchers will gain access to high-quality, authenticated cell lines with increased assay reproducibility.
Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.
A study published in iScience found that cells in breast tissues of women with African ancestry send cues promoting breast cancer growth. Researchers discovered that PZP cells activate epithelial cells, allowing them to invade surrounding tissue.
A study at the University of Zurich tracks live cellular development and epigenetic changes over multiple generations, showing how stress induces heterogeneity and increases genetic complexity. This research may lead to better understanding of cancer cell diversity and develop more effective therapies.
A novel patient-derived organoid library of tongue cancer tissue samples reveals new insights into chemoresistance mechanisms, highlighting the importance of autophagy and cholesterol biosynthesis pathways. The research also identifies potential drug targets for overcoming chemotherapy resistance in tongue cancer.
A new study uses CRISPR-Cas13 to identify nearly 800 noncoding RNAs that are functional and essential for cell function, including in cancer and human development. The researchers found that these RNA molecules modulate key pathways for cell proliferation and can serve as potential biomarkers and therapeutic targets for cancer treatment.
A new study from the University of Texas at Arlington suggests that analyzing RNA in urine can show changes in cell types, revealing early signs of cancer and other diseases. This method could help clinicians detect problems earlier when they are more easily treated without invasive procedures.
Scientists have identified a new mechanism by which cells counteract a key cancer-promoting protein using an 'invisible' protein called RAI2. In cancer cell lines and patient samples, RAI2 levels are reduced in more severe and treatment-resistant forms of prostate cancer.
A novel reporter cell experimental system enables the visualization of sequential changes during endothelial-mesenchymal transition (EndoMT) induced by transforming growth factor-β. Researchers identified CD40 as a potential partial EndoMT marker, which suppresses the transition from partial to full EndoMT.
Researchers created the integrated-gut-liver-on-a-chip platform to examine how gut and liver cells interact, particularly in relation to non-alcoholic fatty liver disease. The study showed significant changes in gene expression and DNA damage when free fatty acids were introduced, leading to cell death similar to severe cases of NAFLD.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
Researchers developed a mathematical model to predict the efficiency of nanoparticle delivery into cells, particularly in stem cells. They found that nanoparticles become trapped in bubble-like vesicles, preventing them from reaching their targets.
Researchers developed a mathematical technique to measure total tumor-specific mRNA levels from bulk tumor sequencing data, associating higher mRNA levels with reduced patient survival. The study suggests this approach could serve as a prognostic biomarker for various cancers, guiding treatment selection.
Researchers have identified a new strain of the myxoma virus that has enabled it to leap from European rabbits to Iberian hares, causing lethal disease in both species. The study suggests that this viral adaptation may also improve the virus's ability to replicate in human cancer cells.
Researchers discover that chemotherapy triggers the secretion of mucins in colorectal cancer cells, forming a physical barrier that prevents drugs from reaching their intended target. The study found potential new biomarkers for disease prognosis and a promising treatment strategy using NCX blockers like SN-6.
Researchers synthesized 30 flavanone derivatives to target NF-kappaB, identifying compounds with potent anti-inflammatory and cytotoxic activities against various cancer cell lines. The top-ranked compounds exhibited improved pharmacological profiles through conjugation of two pharmacophores.
The Broad Institute's Cancer Therapeutics Response Portal (CTRP) has launched to match patients with potentially effective drugs. Researchers can use the portal to find therapeutically exploitable vulnerabilities in different cancer types, identifying genes that may provide new therapeutic targets.
The study found that resveratrol induces cell death in cancer cells with normal p53 expression, but not those with defective p53. Introducing a normal copy of p53 into p53-defective cancer cell lines makes them sensitive to resveratrol's anti-tumor effects.